These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33301810)

  • 1. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
    Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
    Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DFF40-iRGD, a novel chimeric protein with efficient cytotoxic and apoptotic effects against triple-negative breast cancer cells.
    Amrollahi-Nia R; Akbari V; Shafiee F
    Biotechnol Lett; 2021 Oct; 43(10):1967-1976. PubMed ID: 34482510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.
    Mathew M; Zaineb KC; Verma RS
    Apoptosis; 2013 Jul; 18(7):882-95. PubMed ID: 23529188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Simple Methods for Optimizing the Production of "Difficult-to-Express" GnRH-DFF40 Chimeric Protein.
    Barazesh M; Mostafavipour Z; Kavousipour S; Mohammadi S; Mokarram P
    Adv Pharm Bull; 2019 Aug; 9(3):423-431. PubMed ID: 31592077
    [No Abstract]   [Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.
    Aguilar-Rojas A; Huerta-Reyes M; Maya-Núñez G; Arechavaleta-Velásco F; Conn PM; Ulloa-Aguirre A; Valdés J
    BMC Cancer; 2012 Nov; 12():550. PubMed ID: 23176180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
    Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein.
    Ben-Yehudah A; Aqeilan R; Robashkevich D; Lorberboum-Galski H
    Clin Cancer Res; 2003 Mar; 9(3):1179-90. PubMed ID: 12631624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.
    Banas T; Pitynski K; Okon K; Winiarska A
    BMC Cancer; 2018 Apr; 18(1):418. PubMed ID: 29653556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
    Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
    Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy.
    Eaveri R; Ben-Yehudah A; Lorberboum-Galski H
    Curr Cancer Drug Targets; 2004 Dec; 4(8):673-87. PubMed ID: 15578922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.
    Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
    Mol Biol Rep; 2014 Nov; 41(11):7387-94. PubMed ID: 25086620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines.
    Schlick J; Dulieu P; Desvoyes B; Adami P; Radom J; Jouvenot M
    FEBS Lett; 2000 Apr; 472(2-3):241-6. PubMed ID: 10788619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.
    Qi L; Nett TM; Allen MC; Sha X; Harrison GS; Frederick BA; Crawford ED; Glode LM
    Cancer Res; 2004 Mar; 64(6):2090-5. PubMed ID: 15026348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.
    Kulbay M; Johnson B; Fiola S; Diaz RJ; Bernier J
    Biochem Pharmacol; 2021 Dec; 194():114801. PubMed ID: 34678222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin Promoter-Driven DFF40 Gene Expression Sensitizes Melanoma Cancer Cells to Chemotherapy.
    Minaiyan G; Shafiee F; Akbari V
    Int J Toxicol; 2021; 40(4):380-387. PubMed ID: 33960240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.
    Gründker C; Bauerschmitz G; Schubert A; Emons G
    Int J Oncol; 2016 Jun; 48(6):2713-21. PubMed ID: 27098123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.
    Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
    Biochem Cell Biol; 2015 Dec; 93(6):604-10. PubMed ID: 26529233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo.
    Lu Y; Zhang Z; Yan Z; Chen L; Deng W; Lotze M; Wang Z; Lin X; Li LY
    Apoptosis; 2013 Oct; 18(10):1214-23. PubMed ID: 23801079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of an intrinsically fluorescent gonadotropin-releasing hormone receptor and effects of ligand binding on receptor lateral diffusion.
    Nelson S; Horvat RD; Malvey J; Roess DA; Barisas BG; Clay CM
    Endocrinology; 1999 Feb; 140(2):950-7. PubMed ID: 9927328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
    Shariaty Vaziri Z; Shafiee F; Akbari V
    Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.